Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation
Abstract Background Radiofrequency catheter ablation (RFCA) is a widely accepted strategy for eliminating atrial fibrillation (AF). A considerable recurrence rate has partly been ascribed to atrial remodeling. Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) a...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2014-01, Vol.170 (3), p.298-302 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 302 |
|---|---|
| container_issue | 3 |
| container_start_page | 298 |
| container_title | International journal of cardiology |
| container_volume | 170 |
| creator | Cao, Hailong Wu, Ying Li, Qingguo Wu, Yanhu Zhou, Qing Røe, Oluf Dimitri Chen, Yijiang Wang, Ruxing Wang, Dongjin |
| description | Abstract Background Radiofrequency catheter ablation (RFCA) is a widely accepted strategy for eliminating atrial fibrillation (AF). A considerable recurrence rate has partly been ascribed to atrial remodeling. Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) axis may contribute to the development and progression of AF by regulating atrial structural remodeling. This study aimed to determine the relationship between serum soluble RANKL (sRANKL)/OPG and the risk of recurrent arrhythmia after ablation of lone AF. Methods We enrolled 527 lone AF patients undergoing first-time RFCA with complete follow-up data. Pre-ablation venous blood samples were obtained for measurement of serum sRANKL and OPG. Results During the follow-up period of 15 (3–64) months, AF recurred in 187 patients (35.5%). Recurrence was associated with an elevation of serum sRANKL level and sRANKL/OPG ratio. In multivariate survival regression, persistent AF, AF duration, left atrial diameter, amiodarone after ablation, particularly serum sRANKL level and sRANKL/OPG ratio independently predicted AF recurrence. According to ROC curve analysis, the best diagnostic values of serum sRANKL level and sRANKL/OPG ratio for predicting recurrence were 4.89 pmol/l and 0.76, respectively. Conclusions Baseline serum high sRANKL level and sRANKL/OPG ratio are associated with AF recurrence after primary ablation procedure in lone AF patients, and may be used in the prediction of AF recurrence in these patients. |
| doi_str_mv | 10.1016/j.ijcard.2013.08.084 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490780324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0167527313016677</els_id><sourcerecordid>1490780324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-369a6e58786783524f809fb68be4a7d0d6c3898ee3ff37915461fe6914486b6f3</originalsourceid><addsrcrecordid>eNqFkluL1DAUgIMo7uzoPxDpi-BLZ5MmzeVFWBbdFQdXXH0OaXqCqZ12PGmF-femdFTwRQgknHznwsch5AWjO0aZvOp2sfMO211FGd9RnY94RDZMK1EyVYvHZJMxVdaV4hfkMqWOUiqM0U_JRSV4JStqNiQ8AM6HIn2-_vhhf3X_6bY4IrTRTwWCnxFh8FC4MAEW6No4BoQfcw6eCu-mb7DEXdO7KY5DMYaiH4eMTxhdX4TYYOzXv2fkSXB9gufne0u-vnv75eau3N_fvr-53pdeCDWVXBonodZKS6V5XYmgqQmN1A0Ip1raSs-10QA8BK4Mq4VkAaRhQmjZyMC35PVa94hjnjNN9hCThzzFAOOcLBOGKk15FrAlYkU9jikhBHvEeHB4sozaxbDt7GrYLoYt1fksaS_PHebmAO2fpN9KM_DqDLjkXR_QDT6mv5xmjHKjM_dm5SD7-BkBbfJx0d3GrH6y7Rj_N8m_BXwfh5h7focTpG6ccciuLbOpstQ-LNuwLAPj-SWV4r8AuGmv-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490780324</pqid></control><display><type>article</type><title>Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cao, Hailong ; Wu, Ying ; Li, Qingguo ; Wu, Yanhu ; Zhou, Qing ; Røe, Oluf Dimitri ; Chen, Yijiang ; Wang, Ruxing ; Wang, Dongjin</creator><creatorcontrib>Cao, Hailong ; Wu, Ying ; Li, Qingguo ; Wu, Yanhu ; Zhou, Qing ; Røe, Oluf Dimitri ; Chen, Yijiang ; Wang, Ruxing ; Wang, Dongjin</creatorcontrib><description>Abstract Background Radiofrequency catheter ablation (RFCA) is a widely accepted strategy for eliminating atrial fibrillation (AF). A considerable recurrence rate has partly been ascribed to atrial remodeling. Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) axis may contribute to the development and progression of AF by regulating atrial structural remodeling. This study aimed to determine the relationship between serum soluble RANKL (sRANKL)/OPG and the risk of recurrent arrhythmia after ablation of lone AF. Methods We enrolled 527 lone AF patients undergoing first-time RFCA with complete follow-up data. Pre-ablation venous blood samples were obtained for measurement of serum sRANKL and OPG. Results During the follow-up period of 15 (3–64) months, AF recurred in 187 patients (35.5%). Recurrence was associated with an elevation of serum sRANKL level and sRANKL/OPG ratio. In multivariate survival regression, persistent AF, AF duration, left atrial diameter, amiodarone after ablation, particularly serum sRANKL level and sRANKL/OPG ratio independently predicted AF recurrence. According to ROC curve analysis, the best diagnostic values of serum sRANKL level and sRANKL/OPG ratio for predicting recurrence were 4.89 pmol/l and 0.76, respectively. Conclusions Baseline serum high sRANKL level and sRANKL/OPG ratio are associated with AF recurrence after primary ablation procedure in lone AF patients, and may be used in the prediction of AF recurrence in these patients.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2013.08.084</identifier><identifier>PMID: 24326209</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Atrial Fibrillation - blood ; Atrial Fibrillation - mortality ; Atrial Fibrillation - surgery ; Biological and medical sciences ; Biomarkers - blood ; Cardiac dysrhythmias ; Cardiology. Vascular system ; Cardiovascular ; Catheter Ablation - adverse effects ; Catheter Ablation - mortality ; Female ; Follow-Up Studies ; Heart ; Humans ; Kaplan-Meier Estimate ; Lone atrial fibrillation ; Male ; Medical sciences ; Middle Aged ; Osteoprotegerin ; Other treatments ; Predictive Value of Tests ; Preoperative Period ; Radiofrequency catheter ablation ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; RANK Ligand - blood ; Recurrence ; Risk Factors ; Solubility ; Soluble receptor activator of nuclear factor-κB ligand ; Treatment Outcome ; Treatment. General aspects ; Tumors</subject><ispartof>International journal of cardiology, 2014-01, Vol.170 (3), p.298-302</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2013 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2013.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-369a6e58786783524f809fb68be4a7d0d6c3898ee3ff37915461fe6914486b6f3</citedby><cites>FETCH-LOGICAL-c447t-369a6e58786783524f809fb68be4a7d0d6c3898ee3ff37915461fe6914486b6f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2013.08.084$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28110398$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24326209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Hailong</creatorcontrib><creatorcontrib>Wu, Ying</creatorcontrib><creatorcontrib>Li, Qingguo</creatorcontrib><creatorcontrib>Wu, Yanhu</creatorcontrib><creatorcontrib>Zhou, Qing</creatorcontrib><creatorcontrib>Røe, Oluf Dimitri</creatorcontrib><creatorcontrib>Chen, Yijiang</creatorcontrib><creatorcontrib>Wang, Ruxing</creatorcontrib><creatorcontrib>Wang, Dongjin</creatorcontrib><title>Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Abstract Background Radiofrequency catheter ablation (RFCA) is a widely accepted strategy for eliminating atrial fibrillation (AF). A considerable recurrence rate has partly been ascribed to atrial remodeling. Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) axis may contribute to the development and progression of AF by regulating atrial structural remodeling. This study aimed to determine the relationship between serum soluble RANKL (sRANKL)/OPG and the risk of recurrent arrhythmia after ablation of lone AF. Methods We enrolled 527 lone AF patients undergoing first-time RFCA with complete follow-up data. Pre-ablation venous blood samples were obtained for measurement of serum sRANKL and OPG. Results During the follow-up period of 15 (3–64) months, AF recurred in 187 patients (35.5%). Recurrence was associated with an elevation of serum sRANKL level and sRANKL/OPG ratio. In multivariate survival regression, persistent AF, AF duration, left atrial diameter, amiodarone after ablation, particularly serum sRANKL level and sRANKL/OPG ratio independently predicted AF recurrence. According to ROC curve analysis, the best diagnostic values of serum sRANKL level and sRANKL/OPG ratio for predicting recurrence were 4.89 pmol/l and 0.76, respectively. Conclusions Baseline serum high sRANKL level and sRANKL/OPG ratio are associated with AF recurrence after primary ablation procedure in lone AF patients, and may be used in the prediction of AF recurrence in these patients.</description><subject>Adult</subject><subject>Atrial Fibrillation - blood</subject><subject>Atrial Fibrillation - mortality</subject><subject>Atrial Fibrillation - surgery</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cardiac dysrhythmias</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Catheter Ablation - adverse effects</subject><subject>Catheter Ablation - mortality</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lone atrial fibrillation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteoprotegerin</subject><subject>Other treatments</subject><subject>Predictive Value of Tests</subject><subject>Preoperative Period</subject><subject>Radiofrequency catheter ablation</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>RANK Ligand - blood</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Solubility</subject><subject>Soluble receptor activator of nuclear factor-κB ligand</subject><subject>Treatment Outcome</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkluL1DAUgIMo7uzoPxDpi-BLZ5MmzeVFWBbdFQdXXH0OaXqCqZ12PGmF-femdFTwRQgknHznwsch5AWjO0aZvOp2sfMO211FGd9RnY94RDZMK1EyVYvHZJMxVdaV4hfkMqWOUiqM0U_JRSV4JStqNiQ8AM6HIn2-_vhhf3X_6bY4IrTRTwWCnxFh8FC4MAEW6No4BoQfcw6eCu-mb7DEXdO7KY5DMYaiH4eMTxhdX4TYYOzXv2fkSXB9gufne0u-vnv75eau3N_fvr-53pdeCDWVXBonodZKS6V5XYmgqQmN1A0Ip1raSs-10QA8BK4Mq4VkAaRhQmjZyMC35PVa94hjnjNN9hCThzzFAOOcLBOGKk15FrAlYkU9jikhBHvEeHB4sozaxbDt7GrYLoYt1fksaS_PHebmAO2fpN9KM_DqDLjkXR_QDT6mv5xmjHKjM_dm5SD7-BkBbfJx0d3GrH6y7Rj_N8m_BXwfh5h7focTpG6ccciuLbOpstQ-LNuwLAPj-SWV4r8AuGmv-Q</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Cao, Hailong</creator><creator>Wu, Ying</creator><creator>Li, Qingguo</creator><creator>Wu, Yanhu</creator><creator>Zhou, Qing</creator><creator>Røe, Oluf Dimitri</creator><creator>Chen, Yijiang</creator><creator>Wang, Ruxing</creator><creator>Wang, Dongjin</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140101</creationdate><title>Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation</title><author>Cao, Hailong ; Wu, Ying ; Li, Qingguo ; Wu, Yanhu ; Zhou, Qing ; Røe, Oluf Dimitri ; Chen, Yijiang ; Wang, Ruxing ; Wang, Dongjin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-369a6e58786783524f809fb68be4a7d0d6c3898ee3ff37915461fe6914486b6f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Atrial Fibrillation - blood</topic><topic>Atrial Fibrillation - mortality</topic><topic>Atrial Fibrillation - surgery</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cardiac dysrhythmias</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Catheter Ablation - adverse effects</topic><topic>Catheter Ablation - mortality</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lone atrial fibrillation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteoprotegerin</topic><topic>Other treatments</topic><topic>Predictive Value of Tests</topic><topic>Preoperative Period</topic><topic>Radiofrequency catheter ablation</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>RANK Ligand - blood</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Solubility</topic><topic>Soluble receptor activator of nuclear factor-κB ligand</topic><topic>Treatment Outcome</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Hailong</creatorcontrib><creatorcontrib>Wu, Ying</creatorcontrib><creatorcontrib>Li, Qingguo</creatorcontrib><creatorcontrib>Wu, Yanhu</creatorcontrib><creatorcontrib>Zhou, Qing</creatorcontrib><creatorcontrib>Røe, Oluf Dimitri</creatorcontrib><creatorcontrib>Chen, Yijiang</creatorcontrib><creatorcontrib>Wang, Ruxing</creatorcontrib><creatorcontrib>Wang, Dongjin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Hailong</au><au>Wu, Ying</au><au>Li, Qingguo</au><au>Wu, Yanhu</au><au>Zhou, Qing</au><au>Røe, Oluf Dimitri</au><au>Chen, Yijiang</au><au>Wang, Ruxing</au><au>Wang, Dongjin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>170</volume><issue>3</issue><spage>298</spage><epage>302</epage><pages>298-302</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Abstract Background Radiofrequency catheter ablation (RFCA) is a widely accepted strategy for eliminating atrial fibrillation (AF). A considerable recurrence rate has partly been ascribed to atrial remodeling. Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) axis may contribute to the development and progression of AF by regulating atrial structural remodeling. This study aimed to determine the relationship between serum soluble RANKL (sRANKL)/OPG and the risk of recurrent arrhythmia after ablation of lone AF. Methods We enrolled 527 lone AF patients undergoing first-time RFCA with complete follow-up data. Pre-ablation venous blood samples were obtained for measurement of serum sRANKL and OPG. Results During the follow-up period of 15 (3–64) months, AF recurred in 187 patients (35.5%). Recurrence was associated with an elevation of serum sRANKL level and sRANKL/OPG ratio. In multivariate survival regression, persistent AF, AF duration, left atrial diameter, amiodarone after ablation, particularly serum sRANKL level and sRANKL/OPG ratio independently predicted AF recurrence. According to ROC curve analysis, the best diagnostic values of serum sRANKL level and sRANKL/OPG ratio for predicting recurrence were 4.89 pmol/l and 0.76, respectively. Conclusions Baseline serum high sRANKL level and sRANKL/OPG ratio are associated with AF recurrence after primary ablation procedure in lone AF patients, and may be used in the prediction of AF recurrence in these patients.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>24326209</pmid><doi>10.1016/j.ijcard.2013.08.084</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2014-01, Vol.170 (3), p.298-302 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1490780324 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Atrial Fibrillation - blood Atrial Fibrillation - mortality Atrial Fibrillation - surgery Biological and medical sciences Biomarkers - blood Cardiac dysrhythmias Cardiology. Vascular system Cardiovascular Catheter Ablation - adverse effects Catheter Ablation - mortality Female Follow-Up Studies Heart Humans Kaplan-Meier Estimate Lone atrial fibrillation Male Medical sciences Middle Aged Osteoprotegerin Other treatments Predictive Value of Tests Preoperative Period Radiofrequency catheter ablation Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) RANK Ligand - blood Recurrence Risk Factors Solubility Soluble receptor activator of nuclear factor-κB ligand Treatment Outcome Treatment. General aspects Tumors |
| title | Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A56%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20sRANKL/OPG%20predict%20recurrence%20after%20radiofrequency%20catheter%20ablation%20of%20lone%20atrial%20fibrillation&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Cao,%20Hailong&rft.date=2014-01-01&rft.volume=170&rft.issue=3&rft.spage=298&rft.epage=302&rft.pages=298-302&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2013.08.084&rft_dat=%3Cproquest_cross%3E1490780324%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490780324&rft_id=info:pmid/24326209&rft_els_id=1_s2_0_S0167527313016677&rfr_iscdi=true |